One class of IL2 therapeutics seeks to improve upon the properties of Proleukin, a marketed IL2 therapeutic for the treatment of metastatic melanoma and renal cell carcinoma. The gene discussed is IL2; the disease is hereditary clear cell renal cell carcinoma.